Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1412 • 2012 ACR/ARHP Annual Meeting
Vascular Cell Adhesion Molecule (VCAM-1) and Angiostatin in Systemic Lupus Erythematosus
Adnan Kiani¹, Hong Fang¹, Tianfu Wu², Chandra Mohan³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology/Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, ³Internal Medicine/Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Vascular cell adhesion molecule-1 (VCAM-1), an adhesion molecule, is involved in the progression of glomerular and tubulointerstitial injury. High levels of VCAM-1 have been…
Abstract Number: 843 • 2012 ACR/ARHP Annual Meeting
Interferon Regulatory Factor 5 Associates with Systemic Lupus Erythematosus Through Two Distinct and Independent Effects
Erin Zoller¹, Leah C. Kottyan², Bahram Namjou¹, Samuel Vaughn¹, Miranda C. Marion³, Carl D. Langefeld⁴, Marta E. Alarcon-Riquelme⁵, Juan-Manuel Anaya⁶, Elizabeth E. Brown on behalf of PROFILE⁷, Sang-Cheol Bae⁸, Jeffrey C. Edberg⁹, Patrick M. Gaffney¹⁰, Diane L. Kamen¹¹, Robert P. Kimberly¹², Chaim O. Jacob¹³, Joan T. Merrill¹⁴, Kathy Moser Sivils¹⁵, Michelle Petri¹⁶, Rosalind Ramsey-Goldman¹⁷, John D. Reveille¹⁸, Anne M. Stevens¹⁹, Betty P. Tsao²⁰, Luis M. Vila²¹, Timothy J. Vyse²² and Kenneth M. Kaufman²³, ¹Division of Rheumatology and The Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, ⁴Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁶School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ¹²Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ¹⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁸Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ¹⁹Pediatrics, University of Washington, Seattle, WA, ²⁰Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA, ²¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²²Medical & Molecular Genetics, King's College London, London, United Kingdom, ²³1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH
Background/Purpose: Powerful evidence suggests that Systemic lupus erythematous (SLE or lupus) autoimmunity is mediated by disregulation of the IRF5-NFκB signaling pathway. The interferon regulatory factor 5…
Abstract Number: 1387 • 2012 ACR/ARHP Annual Meeting
Hospitalizations and Reasons for Admission in a Clinical SLE Cohort
Alaa Dekis¹, Kenjey Chan¹, Christian A. Pineau², Evelyne Vinet³, Emil P. Nashi², Sasha Bernatsky⁴ and Ann E. Clarke⁴, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Center, Montreal, QC, Canada, ⁴Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Data published from several countries have suggested that patients affected by systemic lupus erythematous (SLE) may have high annual hospitalization rates. However, there is…
Abstract Number: 845 • 2012 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Immune Complexes Upregulate the Expression of CD319 and CD229 On Plasmacytoid Dendritic Cells
Niklas Hagberg¹, Jakob Theorell², Gunnar V. Alm³, Maija-Leena Eloranta⁴, Yenan Bryceson² and Lars Rönnblom⁴, ¹Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ²Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden, ⁴Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden
Background/Purpose: Patients with SLE have an activated type I interferon (IFN) system due to an ongoing IFN-alpha synthesis by plasmacytoid dendritic cells (pDCs) stimulated by…
Abstract Number: 1393 • 2012 ACR/ARHP Annual Meeting
Predictors of Panniculitis in Systemic Lupus Erythematosus
Ashika Odhav¹, Michelle Petri² and Hong Fang², ¹University of Missouri Kansas City School of Medicine, Kansas, MO, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Panniculitis is a rare, but devastating manifestation of SLE. We examined associates of panniculitis in a large SLE cohort. Methods: 52 out of 2,149…
Abstract Number: 663 • 2012 ACR/ARHP Annual Meeting
The Clinical Significance and Expression of P2X7 Purinergic Receptor in Peripheral Blood from Patients with New-Oneset Systemic Lupus Erythematosus
Xiangpei Li¹, Meiyun Wang², Jinhui Tao², Xiaomei Li² and Ning Yu¹, ¹Department of Rheumatology and Immunology,, Anhui Medical University Affiliated Provincial Hospital, Hefei, Anhui, China, ²Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, Hefei, Anhui, China
Background/Purpose: P2X7 purinergic receptor (P2X7R) is encoded by a gene within the human SLE locus SLEB4. Extracellular adenosine triphosphate (ATP) regulates inflammatory cells by activation…
Abstract Number: 1395 • 2012 ACR/ARHP Annual Meeting
The Validation of a New Simple Disease Activity Tool in Systemic Lupus Erythematosus (SLE): The Lupus Activity Scoring Tool (LAST) As Compared to the Sledai Selena Modification
Majed M. Khraishi¹, Rana Aslanov² and Krista Fudge³, ¹Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ²Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada, ³Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada
Background/Purpose: SLE is a chronic autoimmune disease with variable manifestations. New developments in the understanding and treatment of SLE mandated closer monitoring of the disease…
Abstract Number: 633 • 2012 ACR/ARHP Annual Meeting
Missed Work Days in Systemic Lupus Erythematosus
Jie Xu¹, Hong Fang² and Michelle Petri², ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Indirect costs are part of the medical and financial burden of SLE. These costs are easy to undervalue because a significant portion of this…
Abstract Number: 2620 • 2012 ACR/ARHP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled Studies of P140 Peptide in Mannitol (Lupuzor) and Trehalose (Forigerimod) in Patients with SLE
Robert Zimmer¹, Daniel J. Wallace² and Sylviane Muller³, ¹ImmuPharma France, Mulhouse, France, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Institut de Biologie Moléculaire et Cellulaire, CNRS, Strasbourg, France
Background/Purpose: Advances in the understanding of autoimmune diseases pathogenesis have led to the development of peptide-based therapies that aim to potentially reinstate tolerance to self…
Abstract Number: 984 • 2012 ACR/ARHP Annual Meeting
Association of Elevated C5a Levels, but Not the Presence of Anti-Cfh IgG Autoantibodies, with the Deletion of CFHR3 and CFHR1 in SLE
Jian Zhao¹, Seema Kamble¹, Yun Deng¹, Magdangal Erika¹, Daisuke Sakurai², Rongqun Li², Weiling Chen², Jennifer M. Grossman³, Bevra H. Hahn⁴ and Betty P. Tsao⁵, ¹Division of Rheumatology, Department of Medicine,, Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ³Div of Rheumatology, Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Medicine/Rheumatology, Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA
Background/Purpose: We previously reported association of the deletion of complement regulator factor H related CFHR3 and CFHR1 genes (CFHR3-1Δ), rather than CFH exonic SNPs, with…
Abstract Number: 639 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Epratuzumab in an Open-Label Extension Study (SL0006)
K. Hobbs¹, D.J. Wallace², V. Strand³, K. Kalunian⁴, B. Kilgallen⁵, S. Bongardt⁶, W.A. Wegener⁷ and D.M. Goldenberg⁷, ¹Denver Arthritis Clinic, Denver, CO, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Brussels, Belgium, ⁷Immunomedics Inc, Morris Plains, NJ
Background/Purpose: Epratuzumab, a monoclonal antibody targeting CD22, is in development for the treatment of systemic lupus erythematosus (SLE). Two randomized, double-blind trials (ALLEVIATE 1 and…
Abstract Number: 2283 • 2012 ACR/ARHP Annual Meeting
Preferential Association of Complement Receptor 2 Variants with Anti-dsDNA Autoantibodies in Systemic Lupus Erythematosus
Brendan M. Giles¹, Jian Zhao², Kara M. Lough¹, Patrick M. Gaffney on behalf of LLAS2³, Marta E. Alarcon-Riquelme on behalf of BIOLUPUS⁴, Elizabeth E. Brown on behalf of PROFILE⁵, Lindsey A. Criswell⁶, Gary S. Gilkeson⁷, Chaim O. Jacob⁸, Judith A. James⁹, Joan T. Merrill¹⁰, Kathy L. Moser¹¹, Timothy B. Niewold¹², R. Hal Scofield¹³, Timothy J. Vyse¹⁴, John B. Harley¹⁵, Kenneth M. Kaufman¹⁶, Jennifer A. Kelly¹¹, Carl D. Langefeld¹⁷, Jeffrey C. Edberg¹⁸, Robert P. Kimberly¹⁹, Daniela Ulgiati²⁰, Betty P. Tsao²¹ and Susan A. Boackle²², ¹University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ³Arthritis and Immunology Prog, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁷Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁹Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ¹³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Division of Genetics and Molecular Medicine and Division of Immunology, Infection and Inflammatory Disease, King's College London, London, United Kingdom, ¹⁵Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁷Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹⁸Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁹Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²⁰University of Western Australia, Perth, Western Australia, Australia, ²¹Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA, ²²Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Complement receptor 2 (CR2/CD21) is primarily expressed on B cells and follicular dendritic cells (FDC) and is required for normal humoral immune responses. We…
Abstract Number: 992 • 2012 ACR/ARHP Annual Meeting
Functional Genomics of the Human ITGAM Locus
Yebin Zhou¹, Dan C. Bullard¹, Alexander Szalai², Jianming Wu³ and Jeffrey C. Edberg⁴, ¹Genetics, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of alabama at birmingham, Birmingham, AL, ³Veterinary and Biomedical Science, Medicine, University of minnesota, St. Paul, MN, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: ITGAM encodes CD11b, the αM subunit of the Mac-1 -αMβ2 integrin. Mac-1 has many functions on leukocytes including its role as an adhesion molecule…
Abstract Number: 613 • 2012 ACR/ARHP Annual Meeting
Serum Level of Syndecan-1 Is Associated with Disease Activity in Patients with Systemic Lupus Erythematosus
In-Woon Baek¹, Ki-Jo Kim², Ji-Young Kim³, Su-Jung Park³, Chong-Hyeun Yoon⁴, Wan-Uk Kim⁵ and Chul Soo Cho⁶, ¹Internal medicine, Catholic University of Korea, Callege of Medicine, Seoul, South Korea, ²Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, South Korea, ³Internal Medicine, Research Institute of Bone & Joint Diseases, Catholic University of Korea, Seoul, South Korea, ⁴Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁵Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶St Marys Hospital, Seoul, South Korea
Background/Purpose: Syndecan-1(SDC1), a transmemebrane heparan-sulfate glycoprotein, is predominantly expressed by plasma cells and is a receptor for a proliferation-inducing ligand (APRIL). SDC-1 is readily shed…
Abstract Number: 2245 • 2012 ACR/ARHP Annual Meeting
Vitamin D Deficiency Is Associated with, but Does Not Predict, Change in hsCRP in Systemic Lupus Erythematosus (SLE)
Adnan Kiani, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In the general population the cardioprotective effects of vitamin D are thought to be due to modulation of inflammatory cytokines. However, the effects of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].